The influence of therapy on CD4+CD25^highFOXP3+ regulatory T cells in systemic lupus erythematosus patients: a prospective study

References

• Tsokos GC. Systemic lupus erythematosus. N Eng J Med 2011;365:2110–21.
   PubMed Web of Science ®Google Scholar
• Lozovoy M, Simão A, Morimoto H, Iryioda T, Panis C, Reiche E, et al. Hypertension is associated with serologically active disease in patients with systemic lupus erythematosus: role of increased Th1/Th2 ratio and oxidative stress. Scand J Rheumatol 2014;43:59–62.
   PubMed Web of Science ®Google Scholar
• Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005;175:8392–400.
   PubMed Web of Science ®Google Scholar
• Lyssouk EY, Torgashina AV, Soloviev SK, Nassonov EL, Bykovskaia SN. Reduced number and function of CD4CD25highFOXP3 regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol 2007;601:113–19.
   PubMedGoogle Scholar
• Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007;178:2579–88.
   PubMed Web of Science ®Google Scholar
• Bonelli M, Savitskaya A, Von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus. Int Immunol 2008;20:861–8.
   PubMed Web of Science ®Google Scholar
• Tselios K, Sarantopoulos A, Gkougkourelas I, Boura P. CD4CD25highFOXP3 T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective study. Clin Exp Rheumatol 2014 (in press).
   Google Scholar
• Yates J, Whittington A, Mitchell P, Lechler RI, Lightstone L, Lombardi G. Natural regulatory T cells: numbers and function are normal in the majority of patients with lupus nephritis. Clin Exp Immunol 2008;153:44–55.
   PubMed Web of Science ®Google Scholar
• Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008;17:289–94.
   PubMedGoogle Scholar
• Miyara M, Gorochov G, Ehrenstaein M, Musset L, Sakaguchi S, Amoura Z. Human FoxP3 regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011;10:744–55.
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Koch MA. Phenotypic and functional specialization of FOXP3 regulatory T cells. Nat Rev Immunol 2011;11:119–30.
   PubMed Web of Science ®Google Scholar
• Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology 2008;124:13–22.
   PubMed Web of Science ®Google Scholar
• Azab NA, Bassyouni IH, Emad Y, Abd El-Wahab GA, Hamdy G, Mashahit MA. CD4CD25 regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clin Immunol 2008;127:151–7.
   PubMedGoogle Scholar
• Prado C, Gomez J, Lopez P, De Paz B, Gutierrez C, Suarez A. Dexamethasone upregulates FOXP3 expression without increasing regulatory activity. Immunobiology 2011;216:386–92.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
   Google Scholar
• Bertsias G, Ioannidis JPA, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies including Therapeutics. Ann Rheum Dis 2008;67:195–205.
   Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–40.
   PubMed Web of Science ®Google Scholar
• Suarez A, Lopez P, Gomez J, Gutierrez C. Enrichment of CD4CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis 2006;65:1512–17.
   PubMed Web of Science ®Google Scholar
• Lee HY, Hong YK, Yun HJ, Kim YM, Kim JR, Yoo WH. Altered frequency and migration capacity of CD4CD25 regulatory T cells in systemic lupus erythematosus. Rheumatology 2008; 47:789–94.
   PubMedGoogle Scholar
• Zhang B, Zhang X, Tang FL, Zhu LP, Liu Y, Lipsky PE. Clinical significance of increased CD4CD25FOXP3 T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis 2008;67:1037–40.
   PubMed Web of Science ®Google Scholar
• Gomez-Martin D, Diaz-Zamudio M, Vayone G, Crispin JC, Alcocer-Varela J. Quantitative and functional profiles of CD4 lymphocyte subsets in systemic lupus erythematosus patients with lymphopenia. Clin Exp Immunol 2011;164:17–25.
   PubMedGoogle Scholar
• Fattorossi A, Battaglia A, Buzzonetti A, Ciaraffa F, Scambia G, Evoli A. Circulating and thymic CD4CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 2005;116:134–41.
   PubMed Web of Science ®Google Scholar
• Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011;118:3263–72.
   PubMed Web of Science ®Google Scholar
• Barreto M, Ferreira RC, Lourenco L, Moraes-Fontes MF, Santos E, Alves M, et al. Low frequency of CD4CD25 Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants. BMC Immunol 2009;10:5.
   PubMedGoogle Scholar
• Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007; 179:5571–5.
   PubMed Web of Science ®Google Scholar
• Chi LJ, Wang HB, Zhang Y, Wang WZ. Abnormality of circulating CD4()CD25() regulatory T cells in patients with Guillain–Barré syndrome. J Neuroimmunol 2007;192:206–14.
   PubMed Web of Science ®Google Scholar
• Olivito B, Taddio A, Simonini G, Massai C, Ciullini S, Gambineri E, et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol 2010;28:93–7.
   PubMedGoogle Scholar
• Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J Rheumatol 2012;39:1019–25.
   PubMed Web of Science ®Google Scholar
• Costa N, Pires AE, Gabriel AM, Goulart LF, Pereira C, Leal B, et al. Broadened T-cell repertoire diversity in ivig-treated SLE patients is also related to the individual status of regulatory T-cells. J Clin Immunol 2013;33:349–60.
   PubMedGoogle Scholar
• Maddour SM, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol 2010;30 Suppl 1:S4–8.
   Google Scholar
• Wan YY. Regulatory T cells: immune suppression and beyond. Cell Mol Immunol 2010;7:204–10.
   PubMed Web of Science ®Google Scholar